Immuron update on imm-124e sars-cov-2 research

Melbourne, australia, aug. 19, 2022 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; today announced that it has deprioritized sars-cov-2 research to focus on the clinical development of our more advanced stage therapeutic drug candidates.
IMRN Ratings Summary
IMRN Quant Ranking